Make better decisions on the longevity market

Updated October 202670+ pagesPDF

Longevity Reality Check
Cover of NewMarketPitch's Longevity Reality Check report, 2026 edition
How far are longevity promises from reality? Far. Of 7 famous promises, 2 ended, 3 are years behind and 1 was scaled back. Retro’s “10 more healthy years” rests on one safety trial. Chart from NewMarketPitch's Longevity report.
Is Neko Health, the body-scan startup, really worth $7 billion? Not on sales, mostly on promise. Neko sold ~$16M of body scans in 2025 and lost ~$70M. At ~$7B, it is valued at 430 times its sales. Chart from NewMarketPitch's Longevity report.
Is billionaire money behind the longevity startup boom? Partly, almost half of it. Startups founded or bankrolled by famous rich founders took 45% of the $3.75B raised recently, mostly Neko and NewLimit. Chart from NewMarketPitch's Longevity report.
How fast are the top longevity startups rising in value? Fast. Function’s value rose ~10 times in 17 months, to $2.5B. Neko and NewLimit nearly quadrupled in 13 to 18 months, NewLimit with no drug in people. Chart from NewMarketPitch's Longevity report.
NewLimit or Retro: which billionaire’s lab is ahead? Level, 2 of 6 each. Retro (Sam Altman) is first in people, with a pill that is not reprogramming. NewLimit (Brian Armstrong) has more known money and value. Chart from NewMarketPitch's Longevity report.
Do full-body scans find far more scares than cancers? Yes. In the latest review of 17 studies, 78 of 100 people scanned had a finding and ~15 needed more tests for something that was not cancer. ~1 had a cancer. Chart from NewMarketPitch's Longevity report.
Who is ahead in the race to reprogram human cells? Life Biosciences, not the richest lab. It dosed the first person in 2026 and shared early data. Altos and NewLimit are not in people yet. Chart from NewMarketPitch's Longevity report.
Does longevity money go to scans more than to drugs? Yes, since 2025. Scans, blood tests and clinics took 66% of the 2025 money. Drugs caught up in 2026, thanks to NewLimit. Chart from NewMarketPitch's Longevity report.
Did the stock market reward the longevity companies that listed? Mostly not. BioAge lost 69% after a stopped trial, Longeveron and Unity ~100%. Only Insilico, an AI drug-discovery firm, is up (+60%). Chart from NewMarketPitch's Longevity report.

70+ pages in the full report

Swipe· 70+ pages in the report

Inside the report

  • What has changed in the last 12 months
  • What works today, and what’s still hype
  • What are the biggest unsolved problems
  • What technologies are gaining traction
  • Who are the top companies today
  • Who’s ahead, and who’s falling behind
  • What are their valuations
  • Who’s getting funded, and by whom
  • Which business models are winning
  • Which investors are making the biggest bets
  • Where are the biggest opportunities
  • Who are the likely future winners
$99$79one-time payment
Get the report

Verified data with sourcesUpdated in October 2026